The round was led by S3 Ventures, with support from Intuitive Ventures, and a strategic investor. The capital will be deployed toward advancing SERRA-I enrollment, engineering development, and preparation for subsequent studies, including planning for pivotal trials and regulatory interactions.

VahatiCor, a T45 Labs portfolio company, develops innovative medical technology solutions for patients with Coronary Microvascular Dysfunction (CMD), a debilitating condition affecting millions of people who experience chest pain despite having no blockages in their major coronary arteries. The A-FLUX Reducer System® introduces a new therapeutic pathway for patients affected by coronary microvascular dysfunction (CMD), a condition that can cause chest pressure, heaviness, and discomfort. Through this advancement, VahatiCor is helping broaden access to care for individuals who have long faced limited treatment alternatives.